Annual report
2934.TEDINET S100SX2D
Period2022-06-01 → 2023-05-31
Filed2024-02-21
StandardJapan GAAP
ConsolidatedYes
Data checks23 of 23 passed
Amends S100RRVE. Amended by S100SXUN (2024-02-21).
Key figures · 116
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥16.8bn | 2022-06-01 → 2023-05-31 | Cons. | Net sales |
| Revenue | ¥11.9bn | 2021-06-01 → 2022-05-31 | Cons. | Net sales |
| Operating income | −¥1.8bn | 2022-06-01 → 2023-05-31 | Cons. | Operating income |
| Operating income | ¥731m | 2021-06-01 → 2022-05-31 | Cons. | Operating income |
| Ordinary income | −¥1.8bn | 2022-06-01 → 2023-05-31 | Cons. | Ordinary income |
| Ordinary income | ¥712m | 2021-06-01 → 2022-05-31 | Cons. | Ordinary income |
| Profit before tax | −¥1.8bn | 2022-06-01 → 2023-05-31 | Cons. | Income before income taxes |
| Profit before tax | ¥700m | 2021-06-01 → 2022-05-31 | Cons. | Income before income taxes |
| Net income (owners) | −¥1.9bn | 2022-06-01 → 2023-05-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥401m | 2021-06-01 → 2022-05-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥1.9bn | 2022-06-01 → 2023-05-31 | Cons. | Profit loss |
| Net income | ¥400m | 2021-06-01 → 2022-05-31 | Cons. | Profit loss |
| Total assets | ¥7.2bn | at 2023-05-31 | Cons. | Assets |
| Total assets | ¥6.1bn | at 2022-05-31 | Cons. | Assets |
| Total liabilities | ¥4.5bn | at 2023-05-31 | Cons. | Liabilities |
| Total liabilities | ¥1.9bn | at 2022-05-31 | Cons. | Liabilities |
| Net assets / equity | ¥2.7bn | at 2023-05-31 | Cons. | Net assets |
| Net assets / equity | ¥4.2bn | at 2022-05-31 | Cons. | Net assets |
| Net assets / equity | ¥1.3bn | at 2021-05-31d | Cons. | Net assets |
| Cash and deposits | ¥1.6bn | at 2023-05-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥3.0bn | at 2022-05-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥1.6bn | at 2023-05-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.0bn | at 2022-05-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.6bn | at 2021-05-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥1.8bn | 2022-06-01 → 2023-05-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥367m | 2021-06-01 → 2022-05-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥1.1bn | 2022-06-01 → 2023-05-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥860m | 2021-06-01 → 2022-05-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥1.5bn | 2022-06-01 → 2023-05-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥2.6bn | 2021-06-01 → 2022-05-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥-410.6 | 2022-06-01 → 2023-05-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥90.64 | 2021-06-01 → 2022-05-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥86.68 | 2021-06-01 → 2022-05-31 | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥525.78 | at 2023-05-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥907.43 | at 2022-05-31 | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 34.1% | at 2023-05-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 67.8% | at 2022-05-31 | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 9.7% | 2021-06-01 → 2022-05-31 | Cons. | Rate of return on equity (5-year summary) |
| Employees | 255 | at 2023-05-31 | Cons. | Number of employees |
| Employees | 278 | at 2022-05-31 | Cons. | Number of employees |
| Revenue | ¥9.4bn | 2022-06-01 → 2023-05-31 | Standalone | Net sales |
| Revenue | ¥9.3bn | 2021-06-01 → 2022-05-31 | Standalone | Net sales |
| Revenue | ¥8.5bn | 2020-06-01 → 2021-05-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥7.1bn | 2019-06-01 → 2020-05-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥6.1bn | 2018-06-01 → 2019-05-31d | Standalone | Net sales (5-year summary) |
| Operating income | −¥1.7bn | 2022-06-01 → 2023-05-31 | Standalone | Operating income |
| Operating income | ¥751m | 2021-06-01 → 2022-05-31 | Standalone | Operating income |
| Ordinary income | −¥1.7bn | 2022-06-01 → 2023-05-31 | Standalone | Ordinary income |
| Ordinary income | ¥724m | 2021-06-01 → 2022-05-31 | Standalone | Ordinary income |
| Ordinary income | ¥679m | 2020-06-01 → 2021-05-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥174m | 2019-06-01 → 2020-05-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥367m | 2018-06-01 → 2019-05-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | −¥1.7bn | 2022-06-01 → 2023-05-31 | Standalone | Income before income taxes |
| Profit before tax | ¥723m | 2021-06-01 → 2022-05-31 | Standalone | Income before income taxes |
| Net income | −¥1.7bn | 2022-06-01 → 2023-05-31 | Standalone | Profit loss |
| Net income | ¥450m | 2021-06-01 → 2022-05-31 | Standalone | Profit loss |
| Net income | ¥425m | 2020-06-01 → 2021-05-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥96m | 2019-06-01 → 2020-05-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥6m | 2018-06-01 → 2019-05-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥5.8bn | at 2023-05-31 | Standalone | Assets |
| Total assets | ¥5.3bn | at 2022-05-31 | Standalone | Assets |
| Total assets | ¥2.6bn | at 2021-05-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥2.0bn | at 2020-05-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥1.9bn | at 2019-05-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥3.1bn | at 2023-05-31 | Standalone | Liabilities |
| Total liabilities | ¥1.1bn | at 2022-05-31 | Standalone | Liabilities |
| Net assets / equity | ¥2.8bn | at 2023-05-31 | Standalone | Net assets |
| Net assets / equity | ¥4.2bn | at 2022-05-31 | Standalone | Net assets |
| Net assets / equity | ¥1.3bn | at 2021-05-31d | Standalone | Net assets |
| Net assets / equity | ¥843m | at 2020-05-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥746m | at 2019-05-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥814m | at 2023-05-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥2.4bn | at 2022-05-31 | Standalone | Cash and deposits |
| Cash & equivalents | ¥1.6bn | at 2021-05-31d | Standalone | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥902m | at 2020-05-31d | Standalone | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥948m | at 2019-05-31d | Standalone | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥831m | 2020-06-01 → 2021-05-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥218m | 2019-06-01 → 2020-05-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥14m | 2018-06-01 → 2019-05-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥8m | 2020-06-01 → 2021-05-31d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥165m | 2019-06-01 → 2020-05-31d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥63m | 2018-06-01 → 2019-05-31d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥94m | 2020-06-01 → 2021-05-31d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥99m | 2019-06-01 → 2020-05-31d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥130m | 2018-06-01 → 2019-05-31d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥-357.08 | 2022-06-01 → 2023-05-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥101.91 | 2021-06-01 → 2022-05-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥110.75 | 2020-06-01 → 2021-05-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥25.12 | 2019-06-01 → 2020-05-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥1.6 | 2018-06-01 → 2019-05-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥97.45 | 2021-06-01 → 2022-05-31 | Standalone | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥589.16 | at 2023-05-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥918.35 | at 2022-05-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥329.99 | at 2021-05-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥219.25 | at 2020-05-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥194.13 | at 2019-05-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 47.4% | at 2023-05-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 79.0% | at 2022-05-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 48.8% | at 2021-05-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 41.5% | at 2020-05-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 39.0% | at 2019-05-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | -47.5% | 2022-06-01 → 2023-05-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 16.5% | 2021-06-01 → 2022-05-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 40.3% | 2020-06-01 → 2021-05-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 12.2% | 2019-06-01 → 2020-05-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 0.8% | 2018-06-01 → 2019-05-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 4,892,098 | at 2023-05-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 4,757,616 | at 2022-05-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,918,500 | at 2021-05-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,918,500 | at 2020-05-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,918,500 | at 2019-05-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 49 | at 2023-05-31 | Standalone | Number of employees |
| Employees | 54 | at 2022-05-31 | Standalone | Number of employees |
| Employees | 46 | at 2021-05-31d | Standalone | Number of employees |
| Employees | 47 | at 2020-05-31d | Standalone | Number of employees |
| Employees | 42 | at 2019-05-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 71
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2022-06-01 → 2023-05-31 | ¥2m |
| Reconciling Itemsreconciling | depreciation | 2022-06-01 → 2023-05-31 | ¥765,000 |
| Reconciling Itemsreconciling | revenue | 2022-06-01 → 2023-05-31 | −¥186m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-06-01 → 2023-05-31 | −¥186m |
| Reconciling Itemsreconciling | segment assets | at 2023-05-31 | ¥1.3bn |
| Reconciling Itemsreconciling | segment profit | 2022-06-01 → 2023-05-31 | −¥729m |
| Healthcare Marketing Businessreportable segment | capex | 2022-06-01 → 2023-05-31 | ¥4m |
| Healthcare Marketing Businessreportable segment | depreciation | 2022-06-01 → 2023-05-31 | ¥5m |
| Healthcare Marketing Businessreportable segment | employees | at 2023-05-31 | 48 pure |
| Healthcare Marketing Businessreportable segment | revenue | 2022-06-01 → 2023-05-31 | ¥5.2bn |
| Healthcare Marketing Businessreportable segment | revenue external | 2022-06-01 → 2023-05-31 | ¥5.1bn |
| Healthcare Marketing Businessreportable segment | revenue intersegment | 2022-06-01 → 2023-05-31 | ¥185m |
| Healthcare Marketing Businessreportable segment | segment assets | at 2023-05-31 | ¥1.1bn |
| Healthcare Marketing Businessreportable segment | segment profit | 2022-06-01 → 2023-05-31 | ¥39m |
| Healthcare Sales Businessreportable segment | capex | 2022-06-01 → 2023-05-31 | ¥1.1bn |
| Healthcare Sales Businessreportable segment | depreciation | 2022-06-01 → 2023-05-31 | ¥4m |
| Healthcare Sales Businessreportable segment | employees | at 2023-05-31 | 48 pure |
| Healthcare Sales Businessreportable segment | revenue | 2022-06-01 → 2023-05-31 | ¥4.1bn |
| Healthcare Sales Businessreportable segment | revenue external | 2022-06-01 → 2023-05-31 | ¥4.1bn |
| Healthcare Sales Businessreportable segment | segment assets | at 2023-05-31 | ¥2.4bn |
| Healthcare Sales Businessreportable segment | segment profit | 2022-06-01 → 2023-05-31 | −¥28m |
| Medical Care Sales Businessreportable segment | capex | 2022-06-01 → 2023-05-31 | ¥288m |
| Medical Care Sales Businessreportable segment | depreciation | 2022-06-01 → 2023-05-31 | ¥14m |
| Medical Care Sales Businessreportable segment | employees | at 2023-05-31 | 144 pure |
| Medical Care Sales Businessreportable segment | revenue | 2022-06-01 → 2023-05-31 | ¥7.7bn |
| Medical Care Sales Businessreportable segment | revenue external | 2022-06-01 → 2023-05-31 | ¥7.7bn |
| Medical Care Sales Businessreportable segment | revenue intersegment | 2022-06-01 → 2023-05-31 | ¥564,000 |
| Medical Care Sales Businessreportable segment | segment assets | at 2023-05-31 | ¥2.4bn |
| Medical Care Sales Businessreportable segment | segment profit | 2022-06-01 → 2023-05-31 | −¥1.1bn |
| —segment total | employees | at 2023-05-31 | 255 pure |
| Total Of Reportable Segments And Otherssegment total | capex | 2022-06-01 → 2023-05-31 | ¥1.4bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2022-06-01 → 2023-05-31 | ¥23m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-06-01 → 2023-05-31 | ¥17.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-06-01 → 2023-05-31 | ¥16.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-06-01 → 2023-05-31 | ¥186m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2023-05-31 | ¥5.9bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-06-01 → 2023-05-31 | −¥1.1bn |
| Reconciling Itemsreconciling | capex | 2021-06-01 → 2022-05-31 | ¥5m |
| Reconciling Itemsreconciling | depreciation | 2021-06-01 → 2022-05-31 | ¥5m |
| Reconciling Itemsreconciling | revenue | 2021-06-01 → 2022-05-31 | −¥54m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-06-01 → 2022-05-31 | −¥54m |
| Reconciling Itemsreconciling | segment assets | at 2022-05-31 | ¥2.7bn |
| Reconciling Itemsreconciling | segment profit | 2021-06-01 → 2022-05-31 | −¥425m |
| Healthcare Marketing Businessreportable segment | capex | 2021-06-01 → 2022-05-31 | ¥362m |
| Healthcare Marketing Businessreportable segment | depreciation | 2021-06-01 → 2022-05-31 | ¥2m |
| Healthcare Marketing Businessreportable segment | revenue | 2021-06-01 → 2022-05-31 | ¥3.9bn |
| Healthcare Marketing Businessreportable segment | revenue external | 2021-06-01 → 2022-05-31 | ¥3.8bn |
| Healthcare Marketing Businessreportable segment | revenue intersegment | 2021-06-01 → 2022-05-31 | ¥54m |
| Healthcare Marketing Businessreportable segment | segment assets | at 2022-05-31 | ¥1.3bn |
| Healthcare Marketing Businessreportable segment | segment profit | 2021-06-01 → 2022-05-31 | ¥37m |
| Healthcare Sales Businessreportable segment | depreciation | 2021-06-01 → 2022-05-31 | ¥703,000 |
| Healthcare Sales Businessreportable segment | revenue | 2021-06-01 → 2022-05-31 | ¥3.0bn |
| Healthcare Sales Businessreportable segment | revenue external | 2021-06-01 → 2022-05-31 | ¥3.0bn |
| Healthcare Sales Businessreportable segment | segment assets | at 2022-05-31 | ¥251m |
| Healthcare Sales Businessreportable segment | segment profit | 2021-06-01 → 2022-05-31 | ¥779m |
| Medical Care Sales Businessreportable segment | capex | 2021-06-01 → 2022-05-31 | ¥588m |
| Medical Care Sales Businessreportable segment | depreciation | 2021-06-01 → 2022-05-31 | ¥3m |
| Medical Care Sales Businessreportable segment | revenue | 2021-06-01 → 2022-05-31 | ¥5.0bn |
| Medical Care Sales Businessreportable segment | revenue external | 2021-06-01 → 2022-05-31 | ¥5.0bn |
| Medical Care Sales Businessreportable segment | segment assets | at 2022-05-31 | ¥1.9bn |
| Medical Care Sales Businessreportable segment | segment profit | 2021-06-01 → 2022-05-31 | ¥339m |
| Total Of Reportable Segments And Otherssegment total | capex | 2021-06-01 → 2022-05-31 | ¥950m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2021-06-01 → 2022-05-31 | ¥5m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-06-01 → 2022-05-31 | ¥11.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-06-01 → 2022-05-31 | ¥11.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-06-01 → 2022-05-31 | ¥54m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2022-05-31 | ¥3.4bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-06-01 → 2022-05-31 | ¥1.2bn |
| Healthcare Marketing Businessreportable segment | employees | at 2023-05-31 | 10 pure |
| Healthcare Sales Businessreportable segment | employees | at 2023-05-31 | 19 pure |
| Medical Care Sales Businessreportable segment | employees | at 2023-05-31 | 8 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,468
| Item | Context | Value | Unit |
|---|---|---|---|
| Name major shareholders | CurrentYearInstant_No5MajorShareholdersMember | Original text (Japanese)株式会社日本カストディ銀行（年金特金口） | |
| Address major shareholders | CurrentYearInstant_No5MajorShareholdersMember | Original text (Japanese)東京都中央区晴海１丁目８－１２ | |
| Name major shareholders | CurrentYearInstant_No6MajorShareholdersMember | Original text (Japanese)株式会社日本カストディ銀行（信託口） | |
| Address major shareholders | CurrentYearInstant_No6MajorShareholdersMember | Original text (Japanese)東京都中央区晴海１丁目８－１２ | |
| Name major shareholders | CurrentYearInstant_No7MajorShareholdersMember | Original text (Japanese)蓮見 智威 | |
| Address major shareholders | CurrentYearInstant_No7MajorShareholdersMember | Original text (Japanese)東京都港区 | |
| Name major shareholders | CurrentYearInstant_No8MajorShareholdersMember | Original text (Japanese)ファーストヴィレッジ株式会社 | |
| Address major shareholders | CurrentYearInstant_No8MajorShareholdersMember | Original text (Japanese)東京都中央区銀座８丁目５－６ | |
| Name major shareholders | CurrentYearInstant_No9MajorShareholdersMember | Original text (Japanese)野村信託銀行株式会社（投信口） | |
| Address major shareholders | CurrentYearInstant_No9MajorShareholdersMember | Original text (Japanese)東京都千代田区大手町２丁目２－２ | |
| Name major shareholders | CurrentYearInstant_No10MajorShareholdersMember | Original text (Japanese)楽天証券株式会社 | |
| Address major shareholders | CurrentYearInstant_No10MajorShareholdersMember | Original text (Japanese)東京都港区南青山２丁目６－２１ | |
| Issued shares voting rights (text) | FilingDateInstant | Text · Plus | |
| Description issued shares voting rights | CurrentYearInstant_SharesWithNoVotingRightsMember | － | |
| Description issued shares voting rights | CurrentYearInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Description issued shares voting rights | CurrentYearInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Description issued shares voting rights | CurrentYearInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember | － | |
| Description issued shares voting rights | CurrentYearInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | Original text (Japanese)権利内容に何ら限定のない当社における標準となる株式であります。なお、単元株式数は100株であります。 | |
| Description issued shares voting rights | CurrentYearInstant_OrdinarySharesSharesLessThanOneUnitMember | － | |
| Treasury shares etc (text) | FilingDateInstant | Text · Plus | |
| Address of shareholder treasury shares etc | CurrentYearInstant_Row1Member | Original text (Japanese)東京都渋谷区渋谷二丁目９番９号 | |
| Name of shareholder treasury shares etc | CurrentYearInstant_Row1Member | Original text (Japanese)ジェイフロンティア株式会社 | |
| Classes of shares etc (text) | FilingDateInstant | Text · Plus | |
| Acquisitions by resolution of shareholders meeting (text) | FilingDateInstant | Text · Plus | |
| Acquisitions by resolution of board of directors meeting (text) | FilingDateInstant | Text · Plus | |
| Acquisitions not based on resolution of shareholders meeting or board of directors meeting (text) | FilingDateInstant | Text · Plus | |
| Disposals or holding of acquired treasury shares (text) | FilingDateInstant | Text · Plus | |
| Dividend policy (text) | FilingDateInstant | Text · Plus | |
| Overview of corporate governance (text) | FilingDateInstant | Text · Plus | |
| Corporate governance company with corporate auditors (text) | FilingDateInstant | Text · Plus | |
| Information about officers (text) | FilingDateInstant | Text · Plus | |
| Official title or position information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E33800-000NakamuraAtsuhiroMember | Original text (Japanese)代表取締役社長執行役員 | |
| Name information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E33800-000NakamuraAtsuhiroMember | Original text (Japanese)中村 篤弘 | |
| Date of birth information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E33800-000NakamuraAtsuhiroMember | 1980-07-09 | |
| Career summary information about directors and corporate auditors (text) | FilingDateInstant_jpcrp030000-asr_E33800-000NakamuraAtsuhiroMember | Text · Plus | |
| Term of office information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E33800-000NakamuraAtsuhiroMember | Original text (Japanese)(注)３ | |
| Official title or position information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E33800-000KambeSatoshiMember | Original text (Japanese)取締役執行役員COO ヘルスケア事業本部長 | |
| Name information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E33800-000KambeSatoshiMember | Original text (Japanese)神戸 聡 | |
| Date of birth information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E33800-000KambeSatoshiMember | 1969-08-15 | |
| Career summary information about directors and corporate auditors (text) | FilingDateInstant_jpcrp030000-asr_E33800-000KambeSatoshiMember | Text · Plus | |
| Term of office information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E33800-000KambeSatoshiMember | Original text (Japanese)(注)３ | |
| Official title or position information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E33800-000IamuraAkitoshiMember | Original text (Japanese)取締役 | |
| Name information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E33800-000IamuraAkitoshiMember | Original text (Japanese)今村 彰利 | |
| Date of birth information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E33800-000IamuraAkitoshiMember | 1972-12-08 | |
| Career summary information about directors and corporate auditors (text) | FilingDateInstant_jpcrp030000-asr_E33800-000IamuraAkitoshiMember | Text · Plus | |
| Term of office information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E33800-000IamuraAkitoshiMember | Original text (Japanese)(注)３ | |
| Official title or position information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E33800-000FurukawaKazuteruMember | Original text (Japanese)取締役 | |
| Name information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E33800-000FurukawaKazuteruMember | Original text (Japanese)古川 一輝 | |
| Date of birth information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E33800-000FurukawaKazuteruMember | 1973-03-27 | |
| Career summary information about directors and corporate auditors (text) | FilingDateInstant_jpcrp030000-asr_E33800-000FurukawaKazuteruMember | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 23 of 23 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |